Liz Higgins - Haematology Association of Ireland

More documents

Recommendations

Info

Risk factors for poor or failed mobilisation Advanced age Bone marrow involvement by tumour Extensive radiation to marrow sites Extensive prior therapy Mobilisation with G-CSF alone Previous treatment with alkylating agents Prior fludarabine or lenalidomide treatment General physical status Menu
Indication Plerixafor is indicated in combination with G-CSF to enhance mobilisation <strong>of</strong> haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly
Page 1 and 2: AutologousPeripheral Blood Stem Cel
Page 3 and 4: PBSCH 2008 71 2009 75 2010 54 to da
Page 5 and 6: PBSCT PBSCT involves eliminating an
Page 7 and 8: Cancers treated by Autologous PBSCT
Page 9 and 10: Sources of Bone Marrow Stem Cells B
Page 11 and 12: PBSCH COMMISSION DIRECTIVE 2006/17/
Page 13 and 14: PBSC Mobilisation Initial Review FB
Page 15 and 16: Cyclophosphamide 2g/m 2 Chemo on Mo
Page 17 and 18: ICE Etoposide 10mg/m 2 Day 1,2,3.,
Page 19 and 20: Eshap Commence Tuesday Day 12-14
Page 22 and 23: Apheresis guidelines
Page 24: COBE
Page 27: Autologous HSCT in multiple myeloma
Page 31 and 32: Mechanism of action of Plerixafor P
Page 33 and 34: Plerixafor increases predictability

Liz Higgins - Haematology Association of Ireland

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?